Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
06:06pm, Monday, 08'th Sep 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
03:30pm, Monday, 08'th Sep 2025
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL).
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
10:06am, Thursday, 04'th Sep 2025
LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Exelixis, Inc. ("Ex
Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript
07:43pm, Wednesday, 03'rd Sep 2025
Exelixis, Inc. (NASDAQ:EXEL ) Citi's Biopharma Back to School Conference September 3, 2025 3:15 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants D
Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)
03:43pm, Wednesday, 03'rd Sep 2025
Exelixis, Inc. (NASDAQ:EXEL ) 2025 Wells Fargo Healthcare Conference September 3, 2025 12:45 PM EDT Company Participants Michael Morrissey - CEO, President & Director Conference Call Participants Dere
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm
04:49pm, Tuesday, 02'nd Sep 2025
LOS ANGELES--(BUSINESS WIRE)---- $EXEL--EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm.
Exelixis Announces Appointment of Dana T. Aftab, Ph.D.
05:47pm, Friday, 29'th Aug 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:14am, Friday, 29'th Aug 2025
NEW YORK, Aug. 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors a
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September
04:05pm, Wednesday, 27'th Aug 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: 2025 Well
Why Is Exelixis (EXEL) Up 3.8% Since Last Earnings Report?
12:31pm, Wednesday, 27'th Aug 2025
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
10:00am, Wednesday, 27'th Aug 2025
NEW YORK , Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. ("Exelixis" or the "Company") (NASDAQ: EXEL). Such investors are advised to c
Can Label Expansion of Cabometyx Fuel Further Growth for EXEL?
10:36am, Tuesday, 26'th Aug 2025
The FDA approval to expand Exelixis' Cabometyx into neuroendocrine tumors is witnessing encouraging uptake and boosting investor focus.
Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters
06:01pm, Monday, 25'th Aug 2025
CABOMETYX remains the leading TKI in renal cell carcinoma, driving strong revenue growth and expanding into new indications like neuroendocrine tumors. Exelixis's pipeline, led by zanzalintinib, shows
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXEL
12:14pm, Monday, 25'th Aug 2025
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Exelixis, Inc. (“Exelixis” or the “Company”) (NASDAQ: EXEL). Such investors a
Exelixis vs. Merck: Which Oncology Stock Is a Better Pick as of Now?
09:46am, Monday, 25'th Aug 2025
EXEL rides on Cabometyx momentum and pipeline gains, while MRK leans on Keytruda dominance and a diverse portfolio for growth.
